Executive management
Tim Brears, Chief Executive Officer
Tim Brears was appointed Chief Executive Officer of Evonetix in May 2017.
Tim previously served as Chief Executive of a number of bioscience companies, including Xention, a biopharmaceutical company specialising in the discovery and development of ion-channel-modulating drugs for the control of atrial fibrillation, and Gendaq, a company focused on the development of zinc finger proteins for gene regulation.
Prior to that, he spent ten years in the US, initially as a long-term fellow of the European Molecular Biology Organisation at Rockefeller University, New York, and subsequently as Director of Licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina.
Tim is a graduate of Oxford University and holds a PhD in molecular biology from Cambridge University. He also has an MBA from Duke University’s Fuqua School of Business and is a Registered US Patent Agent.
Matthew Hayes, Chief Technology Officer
Matthew Hayes is the Chief Technology Officer of Evonetix, and was a founder member of the team that created the company in 2015.
Before joining Evonetix, Matthew was Head of Technology for the Global Medtech Division of Cambridge Consultants. He joined Cambridge Consultants in 2001, and was responsible for the leadership of many of their largest and most technically challenging projects.
Matthew specialises in multi-disciplinary system design, medical device development, ASIC design and opto-electronics. He holds a PhD and MEng in Electronic Engineering, both from Loughborough University.
Tim Brears, Chief Executive Officer
Tim Brears was appointed Chief Executive Officer of Evonetix in May 2017.
Tim previously served as Chief Executive of a number of bioscience companies, including Xention, a biopharmaceutical company specialising in the discovery and development of ion-channel-modulating drugs for the control of atrial fibrillation, and Gendaq, a company focused on the development of zinc finger proteins for gene regulation.
Prior to that, he spent ten years in the US, initially as a long-term fellow of the European Molecular Biology Organisation at Rockefeller University, New York, and subsequently as Director of Licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina.
Tim is a graduate of Oxford University and holds a PhD in molecular biology from Cambridge University. He also has an MBA from Duke University’s Fuqua School of Business and is a Registered US Patent Agent.
Matthew Hayes, Chief Technology Officer
Matthew Hayes is the Chief Technology Officer of Evonetix, and was a founder member of the team that created the company in 2015.
Before joining Evonetix, Matthew was Head of Technology for the Global Medtech Division of Cambridge Consultants. He joined Cambridge Consultants in 2001, and was responsible for the leadership of many of their largest and most technically challenging projects.
Matthew specialises in multi-disciplinary system design, medical device development, ASIC design and opto-electronics. He holds a PhD and MEng in Electronic Engineering, both from Loughborough University.
Board of directors
Ray Edgson, Non-executive Director
Ray Edgson is the Chief Technology Officer of Cambridge Consultants and a founder member of the team that created Evonetix in 2015. He has been a director of Evonetix since its inception in 2015.
Ray joined Cambridge Consultants in 1986, where he has won and managed many of the company’s largest medical product development programmes in dialysis and medical diagnostics. He has managed the ventures programme since 2001 and been a member of the Cambridge Consultants board since 2007.
Before joining Cambridge Consultants, Ray held positions in the aerospace and industrial equipment sectors.
He holds a degree in Engineering from Brunel University and an MBA from London Business School. He has held numerous directorships and is a Fellow of the Institute of Directors.
Matt Ocko, Non-executive Director
Matt Ocko has three decades of experience as a technology entrepreneur and VC, in the US and globally. Matt’s current investments on behalf of DCVC span from computational drug discovery and synthetic biology to robotics, AI, and large-scale enterprise platforms including quantum computers.
In addition to large IPO outcomes, many of Matt’s prior investments were acquired to become core capabilities of companies like Illumina, Cisco, Google, IBM, Amazon/AWS, VMware, Netapp, and Akamai. His venture investments prior to DCVC include Couchbase, Ayasdi, D-Wave Systems, Uber, AngelList, Fortinet (FTNT), Xensource (CTRX), UltraDNS (NSR), Facebook (FB), and Zoom.us.
Matt founded and was VP of R&D of Da Vinci Systems, a pioneering e-mail software vendor with over 1 million users world-wide prior to its acquisition. Matt holds a degree in Physics from Yale University, and he is an inventor on over 40 granted or in-process patents in areas as diverse as virtualization, fraud detection, and AR.
Nick McCooke, Non-executive Director
Nick McCooke is an experienced and successful bio-entrepreneur, well-known for his pioneering leadership in the Next Generation Sequencing (NGS) space. As CEO of Solexa, he developed the aspirational vision of the $1000 genome. He built and led the team that developed Solexa’s NGS platform and its listing on NASDAQ, which led subsequently to its sale to Illumina, now world leaders in NGS.
Nick has worked in the biotechnology industry for over 30 years, primarily in the areas of NGS and biomarkers. At London-based DNA Electronics, Nick is a key member of the team leading the application of NGS technologies into near-to-patient clinical diagnostics with the LiDia platform. In addition to his non-executive directorship with Evonetix, he is a non-executive director of AIM-listed biotech company Bioventix PLC, chairman of Sydney-based Longas Technologies, chairman of Belgium-based lnc-RNA specialist Biogazelle and a member of the scientific advisory board of venture philanthropy organisation Fondation Fournier-Majoie in Brussels.
He has an MBA from the London Business School.
Tim Brears, Chief Executive Officer
Tim Brears was appointed Chief Executive Officer of Evonetix in May 2017.
Tim previously served as Chief Executive of a number of bioscience companies, including Xention, a biopharmaceutical company specialising in the discovery and development of ion-channel-modulating drugs for the control of atrial fibrillation, and Gendaq, a company focused on the development of zinc finger proteins for gene regulation.
Prior to that, he spent ten years in the US, initially as a long-term fellow of the European Molecular Biology Organisation at Rockefeller University, New York, and subsequently as Director of Licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina.
Tim is a graduate of Oxford University and holds a PhD in molecular biology from Cambridge University. He also has an MBA from Duke University’s Fuqua School of Business and is a Registered US Patent Agent.
Vishal Gulati, Non-executive Director
Dr. Vishal Gulati is one of the Europe’s leading digital healthcare investors. Vishal is a qualified physician and chairman of the Digital Health Forum. Over the last decade he has championed deals across areas including diagnostics, devices & biotech. He is currently on the boards of Horizon Discovery PLC and EcoEos. His investments include Napo Pharmaceuticals, Glenmark, Renovo, Phagenesis. He has also held board positions at Psynova Neurotech, Bioscale and Enigma Diagnostics. Previously, Vishal worked at Atlas Venture, The Wellcome Trust and Radiant Capital.
Hermann Hauser, Investor & Board Observer
Hermann Hauser, entrepreneur and co-founder of Amadeus Capital Partners, supported the foundation of Evonetix in 2015, together with Cambridge Consultants.
In his long and successful career as an entrepreneur and venture capitalist, Hermann has helped start a number of technology companies over the past 40 years, including Acorn Computers and its spin-out ARM, as well as Cambridge Silicon Radio and next-generation DNA sequencing technology company Solexa, which became the market leader and was later acquired by Illumina.
Hermann was awarded an Honorary CBE for ‘innovative service to the UK enterprise sector’ in 2001. In 2004, he was appointed a member of the Government Council for Science & Technology. In 2012, he became a Fellow of the Royal Society in recognition of his contribution to the translation of science into business, in 2013 a Distinguished Fellow of BCS, the Chartered Institute for IT, and in 2015 an Honorary Knight Commander (KBE) for services to engineering and industry.
Hermann holds an MA in Physics from Vienna University and a PhD in Physics from the University of Cambridge. He is a Fellow of the Institute of Physics and of the Royal Academy of Engineering, and an Honorary Fellow of King’s College, Cambridge.